Clinical Research Directory

Inclusion Criteria: * Unilateral/bilateral, upper/lower limb spasticity associated with cerebral palsy. * Naïve to OnabotulinumtoxinA treatment and who, according to medical and to the standard clinical practice criteria, will receive OnabotulinumtoxinA. * Treated only with stable doses of short-acting muscle relaxants can be included in the study, at the investigator's discretion, for at least 30 days prior to treatment starting, under the concept that at the time the steady state of the drug (stable plasma concentrations) will theoretically have been reached. * Under adjuvant treatment with orthoses and other orthopedic devices can be included in the study. * Participants with physio/physical therapy can be included. Exclusion Criteria: * Previously treated with botulinum toxin for spasticity related to cerebral palsy. * Diagnosed with Eaton-Lambert syndrome, myasthenia gravis, or other neurological diseases with compromised neuromuscular transmission. * History of hypersensitivity to the study drug or to any of the excipients in the formulation. * Evidence of inflammation or infection in the anatomical region selected by the investigator for the study drug administration. * Participants under treatment with drugs that interfere with neuromuscular transmission which, at the investigator's discretion, contraindicate OnabotulinumtoxinA concomitant administration. * Have had orthopedic surgery in the segment to be infiltrated in the 12 months prior to drug application.